| Top Adding |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Real Estate > Investing > Negative Cash Flow Should Not Mean No Deal |
|
Top Adding - Negative Cash Flow Should Not Mean No Deal
Many new real estate investors fall into a trap that limits their success. They think that just because a property does According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product not have an initial cash flow under their purchase scenario that it is not a good deal. The first difficulty with this p ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ilosophy is that their purchase scenario may be the problem, not the property. The second quandary may well be that the lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. nvestor simply does not understand the investment nor the property holding period. There are four distinct types of ben here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe efits (or returns) produced by real estate. When you limit your analysis to only one of the four, for example Cash Flow, d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro you do yourself a great disservice. If you try to profit too early you also limit your success. When considering an inv ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc stment in real estate, it would be well to remember that just because a property has negative cash flow doesn’t mean it’ easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi s not a good deal. Remember, Cash Flow is only one of the four kinds of benefits or returns. It may well be possible tha nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically another of the four benefits will more than make up for the negative cash flow. In many cases the tax savings produced and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ by a property will exceed the negative cash outlay. If this is the case, an investor could let the tax savings produced ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi y the property pay the negative cash flow. After all, the tax savings used will be found money. You wouldn’t have them i ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a f you didn’t buy the property. So the property is in fact paying for itself. In this case an investor would be letting t dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e investment pay for itself with the new tax savings it produced. The investor is not financially damaged by the negativ cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin cash flow and the property now has the time to improve sufficiently to maximize the profit potential. This scenario wo tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen uld allow for time to increase rents, reduce expenses and let appreciation do its magic. Any real estate investment that t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel can pay for itself will ultimately produce significant profits for its owner(s). These types of investments need to be h ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ld for a sufficient time period to overcome the negative cash flow and build the equity desired. Just because an invest y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ment property starts out negative, doesn’t mean it’s not a good deal. Do your homework and project the ownership over a . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ariety of holding periods to see if your ultimate profit will meet your goals. It’s not hard to do, and it may mean that elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip you, with your understanding, can now reap the rewards that other less savvy investors pass by. Good luck in your career tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Educational Principles that may Promote Entrepreneurial Behaviour in the 21st Century Start A Bookkeeping Business - Should You Start One? List Building – An Illustration of the ‘Period of Buyer Intensity’ and How to Capitalize On It
|